Truncations of Titin Causing Dilated CardiomyopathyDaniel S. Herman, Christine E. Seidman, Lien Lam et al.|New England Journal of Medicine|2012Cited by 1.5k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Amos Katz, Jens Mogensen et al.|The Lancet|2020Cited by 1.2k
Genotype and Lifetime Burden of Disease in Hypertrophic CardiomyopathyCarolyn Y. Ho, Sharlene M. Day, Euan A. Ashley et al.|Circulation|2018Cited by 837
Myocardial Fibrosis as an Early Manifestation of Hypertrophic CardiomyopathyCarolyn Y. Ho, Christine E. Seidman, Begoña López et al.|New England Journal of Medicine|2010Cited by 706
Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic CardiomyopathySara Saberi, Daniel Jacoby, Nuno Cardim et al.|Circulation|2020Cited by 234